[¹⁸F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer.

ABSTRACT:

Background

In the last years, functional imaging has given a significant contribution to the clinical decision-making of biochemically relapsed prostate cancer (PCa). Hereby, we present a prospective study aiming to validate the role of [¹⁸F]Fluoro-Methyl Choline ([¹⁸F]FMCH) PET/CT in the selection of PCa patients suitable for stereotactic body radiotherapy (SBRT).

Methods

Patients with biochemical recurrence limited up to three lesions revealed by [¹⁸F]FMCH PET/CT were enrolled in the present study and treated with SBRT on all active lesions. Systemic therapy-free survival since the [¹⁸F]FMCH PET/CT was considered as the primary endpoint.

Results

Forty-six patients were evaluated, and a total of 67 lesions were treated. Aft

SUBMITTER: Pasqualetti F 

PROVIDER: S-EPMC6885020 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature